Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) EPS (Basic) (2020 - 2025)

Historic EPS (Basic) for Ovid Therapeutics (OVID) over the last 6 years, with Q3 2025 value amounting to -$168.01.

  • Ovid Therapeutics' EPS (Basic) rose 1336.12% to -$168.01 in Q3 2025 from the same period last year, while for Sep 2025 it was -$502.43, marking a year-over-year increase of 4801.39%. This contributed to the annual value of -$0.37 for FY2024, which is 9994.88% up from last year.
  • Latest data reveals that Ovid Therapeutics reported EPS (Basic) of -$168.01 as of Q3 2025, which was up 1336.12% from -$64.73 recorded in Q2 2025.
  • Ovid Therapeutics' EPS (Basic)'s 5-year high stood at $118.07 during Q2 2024, with a 5-year trough of -$728.12 in Q4 2023.
  • Moreover, its 5-year median value for EPS (Basic) was -$0.21 (2022), whereas its average is -$70.55.
  • As far as peak fluctuations go, Ovid Therapeutics' EPS (Basic) plummeted by 45497500.0% in 2023, and later skyrocketed by 6569444.44% in 2024.
  • Quarter analysis of 5 years shows Ovid Therapeutics' EPS (Basic) stood at -$0.37 in 2021, then soared by 56.76% to -$0.16 in 2022, then plummeted by 454975.0% to -$728.12 in 2023, then skyrocketed by 99.98% to -$0.13 in 2024, then crashed by 128645.49% to -$168.01 in 2025.
  • Its EPS (Basic) stands at -$168.01 for Q3 2025, versus -$64.73 for Q2 2025 and -$141.57 for Q1 2025.